scPharmaceuticals Inc.

2.50
-0.10 (-3.85%)
At close: Apr 24, 2025, 3:59 PM
2.50
0.20%
After-hours: Apr 24, 2025, 04:05 PM EDT
-3.85%
Bid 1.95
Market Cap 125.46M
Revenue (ttm) 36.33M
Net Income (ttm) -85.15M
EPS (ttm) -1.91
PE Ratio (ttm) -1.31
Forward PE -12.48
Analyst Buy
Ask 3.21
Volume 203,725
Avg. Volume (20D) 457,552
Open 2.59
Previous Close 2.60
Day's Range 2.48 - 2.59
52-Week Range 1.94 - 5.65
Beta 0.38

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2017
Employees 162
Stock Exchange NASDAQ
Ticker Symbol SCPH
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 380.96% from the latest price.

Stock Forecasts

Next Earnings Release

scPharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.89%
scPharmaceuticals shares are trading higher after ... Unlock content with Pro Subscription
4 months ago
-5.82%
ScPharmaceuticals shares are trading lower after the company disclosed observed variability during shelf-life testing in one lot of its SCP-111 combination product. This may result in the submission occurring later in 2025.